Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD1656

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 3
  • table 4
Is this relevant?
2014
2014
To study the effect of exogenous i.m. glucagon on recovery from controlled insulin‐induced hypoglycaemia in patients with type 2… Expand
Is this relevant?
Review
2014
Review
2014
Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory… Expand
Is this relevant?
2013
2013
To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add‐on to metformin in patients… Expand
Is this relevant?
2013
2013
To assess the glucose‐lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2… Expand
Is this relevant?
Review
2013
Review
2013
Abstract Glucokinase is an enzyme responsible for the conversion of glucose into glucose-6 phosphate and plays a central role as… Expand
Is this relevant?
2012
2012
Glucokinase plays a central role in glucose homeostasis and small molecule activators of the glucokinase enzyme have been the… Expand
Is this relevant?
2012
2012
CONTEXT Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses… Expand
Is this relevant?
2012
2012
OBJECTIVES AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both… Expand
Is this relevant?
2012
2012
To assess the safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator… Expand
Is this relevant?